<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533256</url>
  </required_header>
  <id_info>
    <org_study_id>Cyto-Sepsis</org_study_id>
    <nct_id>NCT04533256</nct_id>
  </id_info>
  <brief_title>Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis</brief_title>
  <official_title>Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institutul Clinic Fundeni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institutul Clinic Fundeni</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemoadsorption has been demonstrated to improve clinical and paraclinical results in&#xD;
      critically ill patients with sepsis and septic shock. The present study investigates the&#xD;
      effects of three consecutive sessions of hemoadsorption, performed in accordance to the local&#xD;
      protocol for treating patients with sepsis, on organ failure, severity scores and 30-days&#xD;
      mortality. Paraclinical results and severity scores were obtained before and after the three&#xD;
      consecutive sessions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2016</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>28-days mortality</measure>
    <time_frame>28 days after ICU admission</time_frame>
    <description>28-days mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity score</measure>
    <time_frame>3 days</time_frame>
    <description>dynamics of SOFA score (Sequential Organ Failure Assessment) calculated as the mathematical difference in post-therapy SOFA score and pre-therapy SOFA score</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <description>three consecutive sessions of hemoadsorption in patients with sepsis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sepsis or septic shock who require hemoadsorption in accordance with local&#xD;
        guidelines. The decision of hemoadsorption is made by the attending physician prior to&#xD;
        study inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with sepsis or septic shock who require hemoadsorption in accordance with&#xD;
             local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unsigned informed consent&#xD;
&#xD;
          -  duration of therapy under 12 hours&#xD;
&#xD;
          -  death before the three consecutive sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Tomescu, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Fundeni Clinical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institutul Clinic Fundeni</investigator_affiliation>
    <investigator_full_name>Popescu Mihai</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <keyword>organ failure</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>hemoadsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

